Compositions and their uses directed to PTPRU

Details Compositions and their uses directed to PTPRU Compositions and their uses directed to PTPRU

2011-03-01

2011-03-01

Bowman, Amy (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100, C536S024500, C536S024310, C536S024330

Reexamination Certificate

active

07897583

ABSTRACT:
Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease by administration of antisense compounds targeted to PTPRU.

REFERENCES:
patent: 5705623 (1998-01-01), Wiggins et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 6277640 (2001-08-01), Bennett et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2005/0019915 (2005-01-01), Bennett et al.
patent: 2009/0042827 (2009-02-01), Vaillant et al.
patent: WO 93/24510 (1993-12-01), None
patent: WO 94/26764 (1994-11-01), None
patent: WO 2004/094636 (2004-11-01), None
patent: WO 2005/026735 (2005-03-01), None
patent: WO 2005/026735 (2005-03-01), None
Avraham et al., Characterization and chromosomal localization of PTPRO, a novel receptor protein tyrosine phosphatase, expressed in hematopoietic stem cells, 1997, Gene, 204, pp. 5-16.
Zellweger et al., Antitumor Activity of Antisense Clusterin Oligonucleotides is Improved in Vitro and in Vivo by Incorporation of 2′-O-(2-Methoxy)Ethyl Chemistry, 2001, J. Pharmacol Exp Ther, 298(3), pp. 934-940.
Hershman et al., RPTP{micro} and protein tyrosine phosphorylation regulate K+ channel mRNA expression in adult cardiac myocytes, 2000, Am J Physiol, 278, pp. 397-403.
Taniguchi et al., The Receptor Protein Kinase Phosphatase, PTP-RO, Is Upregulated During Megakaryocyte Differentiation and Is Associated With the c-Kit Receptor, 1999, Blood, vol. 94, No. 2, pp. 539-549.
Ostenson et al., Overexpression of Protein-Tyrosinase Phosphatase Is Linked to Impaired Glucose-Induced Insulin Secretion in Hereditary Diabetic Goto-Kakizaki Rats, 2002, Biochemical and Biophysical Research Communications, 291, pp. 945-950.
Aguiar et al., “PTPROt: An Alternatively Spliced and Developmentally Regulated B-Lymphoid Phosphatase That Promoted G0/G1 Arrest” Blood (1999) 94:2403-2413.
Amoui et al., “Expression of a Structurally Unique Osteoclastic Protein-tyrosine Phosphatase Is Driven by an Alternative Intronic Cell Type-specific Promoter” J. Biol. Chem. (2003) 278:44273-44280.
Avraham et al., “Characterization and chromosomal localization of PTPRO, a novel receptor protein tyrosine phosphatase, expressed in hematopoietic stem cells” Gene (1997) 204:5-16.
Beltran et al., “Expression of PTPRO during mouse development suggests involvement in axonogenesis and differentiation of NT-3 and NGF-dependent neurons” J. Comp. Neurol. (2003) 456:384-395.
Branch et al., “A good antisense molecule is hard to fin”TIBS(1998) 23:45-50.
Chin, “On the preparation and Utilization of Isolated and Purified Oligonucleotides” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
Crooke et al., “Basic Principles of Antisense Therapeutics” Antisense Research and Application (1998) Chapter 1:1-50.
Crossland et al., “Molecular cloning and characterization of PTPπ, a novel receptor-like protein-tyrosine phosphatase” Biochem. J. (1996) 319(Pt 1):249-254.
Gait et al., “Applications of Chemically Synthesized RNA” RNA: Protein Interactions, Ed. Smith (1998) 1-36.
Gallo et al., “2′-C-Methyluridine phosphopramidite: a new building block for the preparation of RNA analogues in” Tetrahedron (2001) 57:5707-5713.
Mcardle et al., “Protein Tyrosine Phosphatase Genes Downregulated in Melanoma” J. Invest. Dermatol. (2001) 177:1255-1260.
Mori et al., “Identification of Genes Uniquely Involved in Frequent Microsatellite Instability Colon Carcinogenesis by Expression Profiling Combined with Epigenetic Scanning” Cancer Res. (2004) 64:2434-2438.
Motiwala et al., “Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas” Oncogene (2003) 22:6319-6331.
New England Biolabs 1998/1999 Catalog, cover page, pp. 121 and 284.
Reynolds et al., “Rational siRNA design for RNA interference” Nature Biotechnology (2004) 22(3):326-330.
Sanghvi et al., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications (1993) pp. 273-288.
Scaringe, “RNA Oligonucleotide Synthesis via 5′-Silyl-2′-Orthoester Chemistry” Methods (2001) 23:206-217.
Stepanek et al., “CRYP-2/cPTPRO is a neurite inhibitory repulsive guidance cue for retinal neurons in vitro” J. Cell. Biol. (2001) 154:867-878.
Taniguchi et al., “The Receptor Protein Tyrosine Phosphatase, PTP-RO, Is Upregulated During Megakaryocyte Differentiation and Is Associated With the c-Kit Receptor” Blood (1999) 94:539-549.
Thomas et al., “GLEPP1, a Renal Glomerular Epithelial Cell (Podocyte) Membrane Protein-tyrosine Phosphatase” J. Biol. Chem. (1994) 269:19953-19962.
Wang et al., “Molecular Cloning and Characterization of a Novel Human Receptor Protein Tyrosine Phosphatase Gene, hPTP-K: Down-Regulation of Gene Expression by PMA and Calcium Ionophore in Jukrat T Lymphoma Cells” Biochem. Biophys. Res. Commun. (1997) 231:77-81.
Wang et al., “Transcriptional regulation of a receptor protein tyrosine phosphatase gene hPTP-J by PKC-mediated signaling pathways in Jurkat and Molt-4 T lymphoma cells” Biochem. Biophys. Acta. (1999) 1450:331-340.
Wang et al., “Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM domain family.” Oncogene (1996) 12:2555-2562.
Wharram et al., “Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice aswsociated with hypertension and low glomerular filtration rate” J. Clin. Invest. (2000) 106:1281-1290.
Yan et al., “Physical and Functional Interaction between Receptor-like Protein Tyrosine Phosphatase PCP-2 and B-Catenin” Biochemistry (2002) 41:15854-15860.
Zhang, “Protein-Tyrosine Phosphatases: Biological Function, Structural Characteristics, and Mechanism of Catalysis” Crit. Rev. Biochem. Mol. (1998) 33:1-52.
International Search Report from PCT/US06/20388 dated Jan. 3, 2007.
Czauderna et al., “Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells” Nucleic Acids Research (2003) 31(11):2705-2716.
Suhr et al., “Antisense oligodeoxynucleotide evidence that a unique osteoclastic protein-tyrosine phosphatase is essential for osteoclastic resorption” Journal of Bone and Mineral Research (2001) 16(10):1795-1803.
European Search Report for application EP 06771266.1 dated Oct. 6, 2010.

Affiliated with

Also associated with

Rating

Compositions and their uses directed to PTPRU does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and their uses directed to PTPRU, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and their uses directed to PTPRU will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2723398